10-K: Chicago Atlantic Reports Mixed 2025 Results Amid Cannabis Market Shifts

Chicago Atlantic Real Estate Finance, Inc. reported a slight decrease in net income for 2025, alongside portfolio growth and increased credit loss provisions, as it navigates the evolving cannabis lending landscape.

Summary

• Net income decreased by 3% to $36.01 million in 2025, down from $37.05 million in 2024.
• Gross interest income increased by 1% to $62.94 million in 2025, up from $62.10 million in 2024, driven by an increase in the outstanding principal balance of the loan portfolio.
• Interest expense increased by 5% to $7.55 million in 2025, compared to $7.15 million in 2024, primarily due to a full year of interest expense on $50.0 million senior unsecured notes issued in Q4 2024.
• The loan portfolio's outstanding principal increased to $411.1 million as of December 31, 2025, from $404.7 million as of December 31, 2024.
• The weighted-average yield-to-maturity internal rate of return (YTM IRR) on the loan portfolio decreased from 17.2% in 2024 to 16.3% in 2025, due to re-pricing amendments and new originations with lower YTM IRR.
• The current expected credit loss (CECL) reserve increased by $0.7 million to $5.06 million as of December 31, 2025, representing 1.23% of aggregate loan commitments, up from 1.06% in 2024.
• Four loans were on non-accrual status as of December 31, 2025, with an aggregate principal balance of $48.9 million, compared to one loan ($16.4 million) in 2024.
• The company declared regular cash dividends of $1.88 per common share for 2025, a decrease from $2.06 per common share (including a special dividend) in 2024.
• The Revolving Loan's contractual maturity date was extended from June 30, 2026, to June 30, 2028.
• The company originated a new $5.0 million term loan (Loan #44) to a Missouri cannabis operator in December 2025.
• The U.S. Department of Health and Human Services (HHS) recommended rescheduling cannabis from Schedule I to Schedule III under the CSA, with President Trump issuing an executive order to expedite this process in December 2025.
• The company's management agreement with Chicago Atlantic REIT Manager, LLC was automatically renewed on April 30, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative report due to the decline in net income, increased credit loss provisions, and a higher number of non-accrual loans, despite growth in the loan portfolio and strategic positioning in the cannabis market. The decrease in YTM IRR and dividends also contributes to a cautious outlook.

Positives

• The loan portfolio's outstanding principal increased to $411.1 million in 2025, demonstrating continued growth in lending activities.
• The weighted-average yield-to-maturity internal rate of return (YTM IRR) remains strong at 16.3% as of December 31, 2025, indicating attractive returns on loans.
• The Revolving Loan maturity was extended to June 30, 2028, providing enhanced long-term financing stability.
• The company successfully collected all past due unpaid interest on Loan #9 following its restructuring and incremental advances, bringing the borrower current.
• New loan originations during 2025 had a weighted average real estate collateral coverage of approximately 1.8x, improving the overall portfolio's collateral protection.
• The potential rescheduling of marijuana to Schedule III under federal law is viewed as a catalyst for regulatory reform, expected to positively impact the business and portfolio companies by potentially eliminating Section 280E tax implications and improving free cash flows for borrowers.
• The company maintains a disciplined, credit-first underwriting process and a broad network for originating loans, positioning it as a leading capital provider in the cannabis ecosystem.

Negatives

• Net income decreased by 3% from $37.05 million in 2024 to $36.01 million in 2025.
• The weighted average YTM IRR on the portfolio decreased from 17.2% in 2024 to 16.3% in 2025, partly due to re-pricing amendments and new originations having lower yields.
• The current expected credit loss (CECL) reserve increased by $0.7 million, reflecting increased risk estimates, particularly for loans with higher risk ratings.
• Four loans (Loan #4, #6, #9, #34) were on non-accrual status as of December 31, 2025, with an aggregate principal balance of $48.9 million, indicating increased credit risk and potential for loss.
• The decrease in the Prime rate by 75 basis points during 2025 negatively impacted interest income from approximately 62.4% of the floating-rate loan portfolio.
• Dividends declared per common share decreased from $2.06 in 2024 (including a special dividend) to $1.88 in 2025.
• The company's cash and cash equivalents decreased from $26.4 million in 2024 to $14.9 million in 2025.
• Basic Distributable Earnings per Weighted Average Share decreased from $2.08 in 2024 to $1.92 in 2025.

Risks

• Limited operating history and uncertainty in achieving investment objectives or generating sufficient revenue to sustain distributions.
• Intense competition for capital in the cannabis market, potentially reducing loan returns and affecting operating results.
• Significant risks associated with lending to the cannabis industry due to federal illegality, including potential strict enforcement of federal laws, which could lead to inability to execute the business plan and significant losses.
• Dependence on state laws for cannabis industry growth; adverse changes in state or federal laws or enforcement guidelines could impede business growth.
• Inability to own real estate used in cannabis operations due to statutory prohibitions and exchange listing standards, which may delay or limit remedies in case of borrower default.
• Difficulty selling foreclosed properties due to the specialized nature of cannabis cultivation/processing facilities and a limited number of high-quality operators.
• Certain borrower assets (e.g., licenses, inventory) may not be used as collateral or transferred due to state laws, negatively impacting profitability and recovery in default scenarios.
• As a debt investor, limited ability to influence borrowers' business decisions, which may not align with the company's interests and could decrease loan value.
• Lack of insurance coverage for the company and its borrowers due to involvement in the regulated cannabis industry, exposing them to additional risk and financial liabilities.
• Reliance on the Manager and its key personnel; departure of key individuals or termination of the Management Agreement could adversely affect business.
• Conflicts of interest arising from the relationship with the Manager and its affiliates, including allocation of loan opportunities and compensation arrangements that may incentivize riskier loans.
• Potential for significant losses if the Manager overestimates yields or incorrectly prices risks of loans, or if due diligence fails to reveal all relevant facts.
• Exposure to risks associated with loan participation interests, where the company may not have direct control over rights or remedies.
• Declines in market prices and liquidity in capital markets can result in significant net unrealized depreciation of the portfolio.
• Loans and other assets may be subject to impairment charges, leading to a decline in net carrying value.
• Substantially all debt invested in is unrated, indicating above-average risk and volatility or loss of principal.
• Mezzanine loans, B-Notes, and other subordinated investments expose the company to greater risk of loss.
• Risks associated with debt-oriented real estate investments generally, including economic downturns, changes in laws, and natural disasters.
• Increased risk of loss from construction loans if funding commitments are not met or projects are not completed.
• Potential for loans to be subordinated to other creditors' claims or exposure to lender liability claims.
• Uncertainty and adverse changes in macroeconomic conditions (inflation, interest rates, geopolitical events) could negatively impact financial performance.
• Significant debt incurrence may subject the company to restrictive covenants and increased risk of loss, reducing cash available for distributions.
• Interest rate fluctuations could increase financing costs, decreasing net income and market value of loans.
• Difficulty accessing the services of banks and other financial institutions for the company and its borrowers due to federal illegality of cannabis.
• Changes to state or federal laws regarding hemp, including the 2026 Extensions Act's 'total THC standard' and product limitations, could adversely affect borrowers.
• Cannabis businesses may be subject to federal asset forfeiture, materially affecting loans.
• Inability to access federal bankruptcy courts for cannabis-related businesses, delaying or reducing recovery on collateral.
• Loans involving Canadian entities may be subject to Canadian insolvency protections, restricting foreclosure ability.
• Properties securing loans are subject to extensive local laws and regulatory requirements, which could result in significant costs upon foreclosure.
• The market value of properties securing loans may decrease if they cannot be used for cannabis-related operations.
• REIT distribution requirements may force the company to borrow funds or sell assets under unfavorable market conditions, or forego attractive opportunities.
• Tax on prohibited transactions limits ability to engage in certain asset sales.
• Legislative, regulatory, or administrative tax changes related to REITs could adversely affect the business.
• Dividends payable by REITs generally do not qualify for reduced tax rates, potentially making REITs less attractive to individual investors.
• Board's ability to revoke REIT election without stockholder approval could have adverse consequences.
• REIT requirements may limit effective hedging of operational risks and cause tax liabilities.
• Business interest deductions of subsidiaries may be deferred or disallowed, causing taxable income to exceed cash available for distributions.
• Significant beneficial ownership by Chicago Atlantic founders could exert substantial influence over corporate actions.
• Volatility in the market price of common stock due to various factors, including operating results, regulatory changes, and market perception.
• Future offerings of debt or equity securities could dilute existing stockholders or reduce stock valuation.
• Distributions may be paid from sources other than cash flow from operations, reducing funds for investments or income-producing assets.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Future Outlook

Management believes the executive order to reschedule marijuana to Schedule III represents a catalyst for regulatory reform that would positively impact the business and its portfolio companies, though the timing and ultimate outcome remain uncertain. The company expects continued demand for credit-based solutions in the cannabis industry due to companies preferring less dilutive growth capital and scarce equity capital. It anticipates increasing the principal amount of loans originated and will need to raise additional equity and/or debt financing in the near future to support growth and expanded investment focus. Further interest rate declines are probable, but persistent inflationary pressures and fiscal deficits pose volatility risks.

Management Comments

• Management believes the existence of the Order represents a catalyst to regulatory reform that would have a positive overall impact to our business and that of our portfolio companies; however, there can be no assurance that any such reforms will be fully adopted or such benefits realized.
• Management elected to maintain Loan #9 on non-accrual status as of December 31, 2025 until such time that the borrower demonstrates sustained ability to meet debt service obligations for a minimum of 60 days.
• Management notes that loans risk rated '2' and '3' are generally deemed to be performing loans and generally carry similar CECL reserves.
• Management believes the appraised value of the real estate underlying our loans impacts the amount of the recovery we would receive in each such scenario. However, the amount of any such recovery will likely be less than the appraised value of the real estate and may not be sufficient to pay off the remaining balance on the defaulted loan.
• Management has evaluated subsequent events through the date on which these financial statements were issued. Other than the items listed below, there have been no subsequent events that occurred during such period that required adjustment or disclosure in the consolidated financial statements.

Industry Context

StockSavvy.ai notes that the U.S. cannabis industry continues its rapid state-level growth, with 42 states and D.C. legalizing some form of cannabis by December 31, 2025, and retail sales projected to reach $69 billion by 2031. This expansion, coupled with limited access to traditional banking due to federal illegality, creates a persistent demand for specialized credit solutions like those offered by Chicago Atlantic. The potential federal rescheduling of cannabis to Schedule III, as expedited by President Trump's executive order, is a significant development. While it could ease tax burdens (Section 280E) and potentially improve financial access for cannabis operators, StockSavvy.ai highlights the risk of increased competition from larger financial institutions and pharmaceutical companies, which could compress margins for existing players. The ongoing regulatory uncertainty and fragmentation across states continue to shape the competitive landscape, favoring nimble lenders with deep industry expertise.

Comparison to Industry Standards

• The company's weighted average YTM IRR of 16.3% as of December 31, 2025, is indicative of the higher risk-adjusted returns typically sought and achieved in the specialized cannabis lending market, which often exceeds yields from conventional commercial real estate loans.
• The company's focus on senior loans to state-licensed operators, secured by real estate and other assets, aligns with best practices for mitigating risk in a federally illegal industry where traditional collateral enforcement can be challenging.
• The average real estate collateral coverage of 1.2x for the portfolio as of December 31, 2025, demonstrates a conservative underwriting approach, aiming to provide a buffer against potential losses, which is crucial given the unique regulatory risks of cannabis properties.
• The company's strategy of generally limiting exposure to ground-up construction and lending to operational/profitable facilities differentiates it from some competitors who might take on higher development risks in emerging cannabis markets.
• The weighted average maturity of 2.2 years for the loan portfolio is shorter than typical equity REIT land ownership models (averaging 10+ years), providing greater capital redeployment flexibility in a rapidly evolving regulatory and market environment, a key competitive advantage.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings, nor is any material legal proceeding threatened against it.
• From time to time, the company may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business, including third-parties seeking to impose liability in connection with loans.

Related Party Transactions

• The Management Agreement with Chicago Atlantic REIT Manager, LLC (an affiliate of Chicago Atlantic Group, LP) governs management fees, incentive compensation, and expense reimbursements. For 2025, total management and incentive fees earned were $8.20 million, and general and administrative expenses reimbursable to the Manager were $4.93 million.
• As of December 31, 2025, affiliates of the company co-invested in 17 of the 26 portfolio companies, raising potential conflicts of interest in loan allocation and control rights.
• John Mazarakis, Executive Chairman, was appointed CEO and Co-Executive Chairman of Vireo Growth Inc. in December 2024, a former portfolio company and related party. Affiliated investment funds managed by entities under common control with the Manager also hold material equity interests in Vireo, creating conflicts of interest regarding Mr. Mazarakis's time and attention.
• Loan #9 (comprised of a Judgment Loan and Term Loan) is classified as a related party loan with a carrying value of approximately $29.0 million as of December 31, 2025. The company made incremental advances of $12.6 million to this borrower in 2025, which was brought current on interest payments, but remains on non-accrual status.
• Loan #18 to FarmaceuticalRX, LLC (FRX) is a related party loan with a carrying value of $47.1 million as of December 31, 2025, due to common control affiliates exercising significant influence over FRX.
• Loans #3 and #33 (fully repaid in July 2025) were to affiliates of Vireo Growth, Inc., classified as related party transactions due to Mr. Mazarakis's role and affiliated investment funds' equity interests in Vireo.
• In 2024, the company sold $6.0 million of Loan #11 principal to an affiliate and exchanged $6.0 million of Loan #1 principal for existing Loans #7 and #20 from an affiliate. Also, Loan #26 was refinanced by an affiliate for $6.5 million.

Stakeholder Impact

• Shareholders: Potential for reduced total return due to decreased net income and dividends, increased credit loss provisions, and the possibility of future distributions from non-operating cash flows. The volatility of common stock price and potential dilution from future capital raises are also impacts. The potential federal rescheduling of cannabis could positively impact shareholder value by improving borrower cash flows and reducing tax burdens.
• Employees (of Manager): Stock-based compensation increased, indicating continued incentives for the Manager's personnel. Management changes, such as the appointment of David Kite as President, could affect internal dynamics.
• Customers (Borrowers): Continued access to specialized debt capital in the cannabis industry, which is underserved by traditional banks. However, non-accrual status on some loans indicates challenges for certain borrowers. Potential federal rescheduling could significantly benefit borrowers by easing tax burdens and improving access to financial services.
• Creditors: Increased debt (Notes Payable) and utilization of the Revolving Loan indicate reliance on debt financing. The increase in CECL reserve and non-accrual loans suggests higher credit risk exposure for lenders.
• Regulatory Authorities: The company's operations are subject to ongoing scrutiny regarding REIT qualification, Investment Company Act exemption, and compliance with evolving federal and state cannabis laws. The potential rescheduling of cannabis will require significant regulatory adjustments.

Next Steps

• Monitor the federal administrative rulemaking process for rescheduling marijuana to Schedule III, including potential legal and procedural challenges, and assess its impact on tax treatment, market dynamics, and competition.
• Continue to monitor federal and state cannabis-related regulatory developments and assess their potential impact on business, financial condition, and results of operations.
• Actively monitor and manage the four loans currently on non-accrual status (Loan #4, #6, #9, #34) and pursue rights and remedies under loan documents as needed.
• Management will continue to maintain Loan #9 on non-accrual status until the borrower demonstrates sustained ability to meet debt service obligations for a minimum of 60 days.
• Continue to implement the growth strategy by targeting loans with specific characteristics (real estate collateral coverage, well-capitalized operators, limited license jurisdictions).
• Diversify financing sources with increased access to equity and debt capital to support portfolio growth.
• Regularly evaluate loans and retain independent third-party valuation firms for unquoted assets, including determination of reserves for credit losses.
• The company expects to raise additional equity and/or debt funds in the near future to increase liquidity and support its expanded investment focus.
• The revised hemp provisions under the 2026 Extensions Act are scheduled to take effect on November 12, 2026, requiring ongoing monitoring of regulatory implementation and enforcement practices.

Key Dates

Recommendation

The company operates in a high-growth, yet high-risk, niche market (cannabis lending). While the loan portfolio is growing and the YTM IRR remains attractive, the decline in net income, increase in non-accrual loans, and higher CECL reserve for 2025 indicate rising credit quality concerns and operational headwinds. The potential federal rescheduling of cannabis is a significant positive catalyst, but its timing and full impact are uncertain. The stock's volatility and the inherent risks of the cannabis industry, coupled with the company's reliance on external management and related-party transactions, suggest a 'hold' recommendation. Investors should monitor credit quality trends, the pace of federal regulatory reform, and the company's ability to manage its non-accrual loans and maintain dividend stability.

Keywords

Commercial Mortgage REIT, Cannabis Industry Lending, Real Estate Finance, SEC 10-K, REIT Taxation, Loan Portfolio, Credit Risk, Interest Rates, Federal Cannabis Policy, State Legalization, Financial Performance, Corporate Governance, Investment Strategy, Debt Financing, Equity Capital, Distributable Earnings, CECL Reserve, Non-accrual Loans, Management Agreement, Shareholder Distributions